ASAnurag Saxena

Anurag Saxena

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anurag Saxena has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Oksana Moshynska

    Affiliation of authors: Department of Pathology, Royal University Hospital and College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

    5 shared publications
  • David P. Sheridan

    Department of Internal Medicine (Division of Hematology), Royal University Hospital and College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

    2 shared publications
  • Koravangattu Sankaran

    Department of Pediatrics, Royal University Hospital and College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

    2 shared publications
  • Leonard F. Skinnider

    Department of Pathology, Royal University Hospital, University of Saskatchewan, Saskatoon, Canada

    2 shared publications
  • O Moshynska

    Department of Pathology, Royal University Hospital, Saskatoon, Saskatchewan S7N 0W8, Canada

    2 shared publications
  • Sathiyanarayanan Viswanathan

    Department of Pathology, Royal University Hospital and College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

    2 shared publications

Latest Publications

  • Open Access

    RESPONSE: Re: Prognostic Significance of a Short Sequence Insertion in the MCL-1 Promoter in Chronic Lymphocytic Leukemia

    by Oksana Moshynska, Anurag Saxena

    The Correspondences by Freeman et al., Vargas et al., Iglesias-Serret et al., Nenning et al., and Dicker et al. address four key points regarding MCL-1 promoter nucleotide insertions.


    • 1 April 2005
      • Vol. 58  (4) , 447-8

    Monckeberg medial calcific sclerosis mimicking malignant calcification pattern at mammography.

    by A Saxena, I C Waddell, R W Friesen, R T Michalski


  • Open Access

    Initial diagnosis of small lymphocytic lymphoma in parotidectomy for Warthin tumour, a rare collision tumour

    by A Saxena, B Memauri, W Hasegawa

    Warthin tumours (WT) and malignant lymphomas are only rarely associated, and most are examples of involvement of the lymphoid stroma of WT by a disseminated lymphoma. This report describes a case where excision of a parotid mass led to the initial diagnosis of WT and small lymphocytic lymphoma (SLL). The diagnosis of SLL was confirmed by immunohistochemistry and molecular studies. The patient had stage IV A disease and is currently in chemotherapy induced complete remission. This case highlights the extremely rare association of SLL with WT and the importance of evaluation of the WT stroma, where the pale proliferation centres of SLL may mimic germinal centres of reactive lymphoid nodules.


  • G125A single-nucleotide polymorphism in the human BAX promoter affects gene expression

    by Oksana Moshynska, Igor Moshynskyy, Vikram Misra, Anurag Saxena

    Earlier we had reported a guanine to adenosine substitution at position 125 (G125A) in the BAX promoter, and its association with higher stage of the disease and failure to achieve complete response to treatment in chronic lymphocytic leukemia (CLL) patients. The aim of this study was to test the hypothesis that G125A leads to a reduction in the transcription of the BAX gene and that this is a direct cause of altered BAX mRNA and protein expression. In lymphocytes of CLL patients, BAX mRNA expression was determined by RNase protection assay and Bax protein was detected by immunoblotting. The presence of G125A in the BAX promoter was associated with lower BAX mRNA (P=0.004) and protein (P=0.024) levels. In transient expression assays using wild-type and mutant BAX promoter sequences linked to Luciferase as a reporter, the G125A polymorphism reduced expression of the BAX promoter by 2.6-fold. These studies suggest a mechanism for the biological effect of the G125A.


  • Open Access

    Clonal B cell populations in a minority of patients with Hashimoto’s thyroiditis

    by A Saxena, E C Alport, O Moshynska, R Kanthan, M A Boctor

    Background: Hashimoto’s thyroiditis (HT) is a risk factor for thyroid lymphoma, and clonal B cell populations in HT support this link. The literature on B cell clonality in HT is controversial. Aims: To identify clonal B cell populations in HT and to assess their usefulness in differentiating HT from mucosa associated lymphoid tissue (MALT) lymphoma and predicting future development of lymphoma. Methods: DNA from formalin fixed, paraffin wax embedded blocks of thyroid specimens from 10 patients with HT and two thyroid MALT lymphomas was analysed for B cell clonality by seminested polymerase chain reaction (PCR) using FRIII/LJH and FRIII/VLJH primers to amplify the IgH gene VDJ region. In one case, PCR products were sequenced. Immunohistochemistry was performed by labelled streptavidin–biotin technique using antibodies to: CD45, CD45RO, CD3, CD20, and cytokeratin. Results: The histopathological and clinical findings were characteristic of HT. Clonal bands were seen in three and a polyclonal smear pattern was seen in seven cases. The clonal bands in HT were associated with a background smear, and could not be reproduced from other blocks from the same case or from deeper sections of the same block. The clonal bands in thyroid lymphomas were not associated with a background smear and were reproducible. None of the patients with clonal B cells has developed malignant lymphoma during a follow up of 10–13 years. Conclusions: B cell clonal bands in HT have different features from those in lymphoma (non-pure and non-reproducible) and do not predict future development of lymphoma.


  • Open Access

    Mcl‐1 and Bcl‐2/Bax ratio are associated with treatment response but not with Rai stage in B‐cell chronic lymphocytic leukemia

    by Anurag Saxena, Sathiyanarayanan Viswanathan, Oksana Moshynska, Puneeta Tandon, Koravangattu Sankaran, David P. Sheridan

    Although both Bcl‐2/Bax ratio and Mcl‐1 have been identified to be of clinical relevance in B‐cell chronic lymphocytic leukemia (CLL), there is controversy regarding their role; further, their relative importance is not well delineated. Expression of Bcl‐2, Bax, the Bcl‐2/Bax ratio, and Mcl‐1 in 51 consecutive previously untreated CLL patients and 16 controls was determined by Western blotting. Only 37 patients were treated, all with chlorambucil and prednisone initially. Six patients achieved complete response (CR), 14 were non‐responders (NR), and 17 had a partial response (PR), as defined by NCI criteria. There was considerable inter‐patient variability in protein expression and overlap with healthy volunteers (P > 0.05). All patients with CR had low Mcl‐1 levels compared to the PR + NR group (0.07 ± 0.02 vs. 0.14 ± 0.07, P = 0.043). Higher Mcl‐1 expression as determined by dichotomizing the data was associated with a failure to achieve CR (P = 0.021). The Bcl‐2/Bax ratio was significantly associated with treatment response only when CR and PR were considered together (0.89 ± 0.53 [CR + PR] vs. 3.38 ± 4.47 [NR], P = 0.0118). There was no association with Rai stage. Low Mcl‐1 appears to be a requirement for CR, while low Bcl‐2/Bax ratio is indicative of some response to conventional treatment. Am. J. Hematol. 75:22–33, 2004.


  • Open Access

    Molecular detection of the G(-248)A BAX promoter nucleotide change in B cell chronic lymphocytic leukaemia

    by O Moshynska, K Sankaran, A Saxena

    Background: A novel single nucleotide polymorphism (SNP), G(−248)A, in the 5′ untranslated region of the BAX promoter and its association with reduced protein expression, progression beyond Rai stage 0, and treatment resistance in chronic lymphocytic leukaemia (CLL) has been reported previously. Aim: To develop a restriction enzyme analysis (REA) based method for routine detection of BAX promoter SNP in a clinical laboratory. Methods: The BAX promoter was analysed in duplicate by REA and sequencing in 90 samples (from 45 patients with CLL, 43 controls, and two cell lines). The promoter region was amplified, digested with restriction endonucleases (Aci I and Tau I), and separated by gel electrophoresis. Results: After digestion, the normal GG genotype samples produced three distinct bands. The homozygous AA replacement abolished the cleavage site, resulting in a single band. Although the heterozygous samples produced three bands, the two smaller visible bands were reduced in intensity (> 50%). The test characteristics of Aci I REA were better than those of Tau I REA, in terms of sensitivity (100% v 77.8%), specificity (98.6% v 92.3%), positive predictive value (95.03% v 87.4%), and negative predictive value (100% v 85.83%). Conclusions: REA using Aci I is a highly sensitive and specific method for detecting the BAX G(-248)A SNP in CLL.


  • Posttransplant diffuse large B-cell lymphoma of "lymphomatoid granulomatosis" type

    by A. Saxena, K. Dyker, S. Angel, O. Moshynska, S. Dharampaul, D. Cockroft

    The exact relationship between lymphomatoid granulomatosis (LyG) and posttransplant lymphoproliferative disorders (PTLDs) is not clear. Both are observed in immunodeficient patients and are Epstein-Barr virus driven. These disorders are, however, considered distinct based upon the immune response elicited; LyG is T-cell rich while PTLDs are T-cell poor. We describe a case of LyG-type diffuse large B-cell lymphoma (DLBCL) in a lung transplant recipient. The unusual features include rare occurrence of LyG in a posttransplant setting, systemic involvement by LyG variant of DLBCL in a solid organ transplant recipient, paucity of T-cells in this LyG type lymphoma, and subcutaneous panniculitic pattern in a B-cell lymphoproliferative disorder. This first report of systemic LyG variant of DLBCL in a posttransplant setting has features suggesting similarities and overlap between LyG and PTLD.


  • Expression of Bcl‐x, Bcl‐2, Bax, and Bak in endarterectomy and atherectomy specimens

    by A. Saxena, J. D. McMeekin, D. J. Thomson

    The regulation of apoptosis in atherosclerosis is not completely defined. The aim of this study was to determine the expression of Bcl‐2, Bcl‐x, Bax, and Bak in relation to apoptosis in advanced atherosclerotic lesions. In atherectomy (15), endarterectomy (10), and control non‐atherosclerotic segments of renal (2) and of coronary and carotid (5) arteries, the extent of apoptosis was determined using TdT dUTP nick end labelling (TUNEL) and nuclear morphology (karyorrhexis/pyknosis) and expression of apoptosis regulators by immunohistochemistry and western blot analysis on paraffin‐embedded material. In all specimens, the atherosclerotic involvement was advanced: grade V (n=18) and grade VI (n=7). The apoptotic index was high (mean 30%) in advanced lesions compared with controls (<2%) and smooth muscle cells (SMCs) were the predominant cell type undergoing apoptosis. In all TUNEL‐positive apoptotic cells, Bax and Bak were present, while Bcl‐x was absent. Bcl‐2 was absent in a majority of these cells, but occasional TUNEL‐positive cells expressed Bcl‐2. In non‐apoptotic cells, Bcl‐x was present and western blot detected only the long isoform, Bcl‐xL, from the plaques. In conclusion, increased Bax and Bak coupled with lack/paucity of Bcl‐2 and Bcl‐xL are associated with SMC apoptosis in advanced lesions. Bcl‐xL in non‐apoptotic cells appears to contribute to prolonged cell survival. Copyright © 2002 John Wiley & Sons, Ltd.